Taiwan Advance Bio-Pharmaceutical (ROCO:4186) EV-to-EBITDA : 68.84 (As of May. 26, 2024)

Taiwan Advance Bio-Pharmaceutical EV-to-EBITDA Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					-12.90	-59.51	-22.93	44.22	76.27

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-22.93	-	44.22	-	76.27

Competitive Comparison of Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA

For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA falls into.

Taiwan Advance Bio-Pharmaceutical EV-to-EBITDA Calculation

Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA for today is calculated as:

Taiwan Advance Bio-Pharmaceutical's current Enterprise Value is NT$1,501.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$21.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical  (ROCO:4186) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Taiwan Advance Bio-Pharmaceutical's PE Ratio for today is calculated as:

Taiwan Advance Bio-Pharmaceutical's share price for today is NT$15.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-0.123.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Taiwan Advance Bio-Pharmaceutical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Business Description